Post‐radiotherapy cribriform‐morular thyroid carcinoma

BACKGROUND: According to the new 2022 World Health Organization classification of endocrine tumors, thyroid malignancy, formerly known as the cribriform‐morular variant of papillary thyroid carcinoma, is now categorized as differentiated thyroid malignancy; it is, at present, called cribriform‐morul...

Descripción completa

Detalles Bibliográficos
Autores principales: Or Koca, Arzu, Güler Şimşek, Gülçin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833981/
https://www.ncbi.nlm.nih.gov/pubmed/36535913
http://dx.doi.org/10.1002/jcla.24819
Descripción
Sumario:BACKGROUND: According to the new 2022 World Health Organization classification of endocrine tumors, thyroid malignancy, formerly known as the cribriform‐morular variant of papillary thyroid carcinoma, is now categorized as differentiated thyroid malignancy; it is, at present, called cribriform‐morular thyroid carcinoma and classified as a tumor of unknown histogenesis. CASE REPORT: In this case report, we report on a 15‐year‐old patient who underwent external radiotherapy to the neck for Hodgkin's disease and developed cribriform‐morular thyroid carcinoma 5 years after radiotherapy. CONCLUSIONS: We believe that cribriform‐morular thyroid carcinoma with diffuse nuclear beta‐catenin expression has exciting and unresolved uncertainties that may affect disease prognosis and follow‐up for cytopathologists and endocrinologists.

Ejemplares similares